Nutex Health (NASDAQ:NUTX) Releases Earnings Results, Beats Estimates By $0.17 EPS

Nutex Health (NASDAQ:NUTX) posted its earnings results on Thursday. The company reported $5.71 EPS for the quarter, topping the consensus estimate of $5.54 by $0.17, FiscalAI reports. The company had revenue of $217.61 million during the quarter, compared to the consensus estimate of $214.82 million. Nutex Health had a net margin of 21.25% and a return on equity of 39.74%.

Nutex Health Stock Down 6.8%

Shares of NASDAQ NUTX traded down $13.08 during mid-day trading on Friday, reaching $180.56. 167,920 shares of the company were exchanged, compared to its average volume of 167,060. The firm has a 50-day moving average of $203.37 and a 200 day moving average of $151.24. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of 7.09 and a beta of 0.66. The company has a quick ratio of 4.96, a current ratio of 5.00 and a debt-to-equity ratio of 0.59. Nutex Health has a 1 year low of $83.99 and a 1 year high of $226.16.

Insider Buying and Selling

In other Nutex Health news, Director Scott Saunders sold 203 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $214.25, for a total value of $43,492.75. Following the sale, the director directly owned 400 shares of the company’s stock, valued at approximately $85,700. This represents a 33.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 44.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NUTX. B. Riley Financial reissued a “buy” rating on shares of Nutex Health in a report on Friday, September 4th. LADENBURG THALM/SH SH started coverage on Nutex Health in a report on Monday, October 26th. They issued a “buy” rating and a $336.00 target price for the company. Wall Street Zen lowered Nutex Health from a “buy” rating to a “hold” rating in a research note on Saturday, October 31st. Weiss Ratings upgraded shares of Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, October 6th. Finally, Lake Street Capital reissued a “buy” rating and set a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research note on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $323.67.

About Nutex Health

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.